Clarus Ventures is a life sciences-focused investment firm with $1.7 billion under management, with offices in Boston and San Francisco. Founded in late-2005 by an experienced team with deep development expertise, Clarus has made more than 50 investments in the life sciences space.
Clarus recently announced Clarus Lifesciences III, a $500 million fund that will be split evenly between traditional venture investments and R&D risk-sharing partnerships with midcap and large pharmaceutical companies. For its venture portfolio, Clarus is seeking passionate entrepreneurs who are advancing innovative programs that target significant unmet medical needs, with an emphasis on therapeutics. Clarus invests in therapeutics at all stages of development and is agnostic as to therapeutic indication. Clarus’ medtech focus is on commercial stage opportunities with disruptive potential.
Scott Requadt, Managing Director, will be presenting on November 19th. He will offer insights and lessons learned from case studies of two investments that he has been involved with — one in therapeutics and one in medtech. Ari Brettman, MD, Associate at Clarus Ventures, as well as Scott, will also be on hand to meet with a handful of pre-approved companies one-on-one after the presentation.
To be considered for a one-on-one meeting, please complete the information required here.
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
12:00pm | Networking Lunch
12:30-4:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on October 22nd.
About Clarus Ventures:
Clarus Ventures is a global investment firm dedicated to life sciences. Founded in 2005 by a team of accomplished investment and operating professionals, we approach healthcare investing with a passion for novel ideas and the discipline to generate attractive and predictable returns. Clarus manages $1.7 billion of assets across three funds. Through multiple platforms, we have invested in over 50 private and public companies in the biotechnology, medical device, and diagnostic spaces. Our team’s expertise has enabled us to establish a long history of creating value through partnerships with Entrepreneurs, The Biopharmaceutical and Medical Technology industries to develop cutting-edge therapeutics, devices and diagnostics. Our diverse network has allowed us to source and capitalize on unique investment opportunities. In every investment, we employ a hands-on philosophy and adhere to our investment principals which are founded on our core competencies of development and clinical expertise, regulatory knowledge, and the ability to adapt to an ever-changing investment landscape. We strive to generate outstanding returns for our investors and thrive on discovering and developing innovative products that improve people’s lives.
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until November 18th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on October 22nd. Your application will be reviewed and you will be notified of acceptance on November 5th. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
Send this to a friend